RSCI (Redwood Scientific Technologies) Debt-to-Equity: 0.00 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Redwood Scientific Technologies Debt-to-Equity?

Redwood Scientific Technologies RSCI Debt-to-Equity is 0.00 as of Dec. 2023.

Redwood Scientific Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Redwood Scientific Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Redwood Scientific Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.20 Mil. Redwood Scientific Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Redwood Scientific Technologies's Debt-to-Equity or its related term are showing as below:

RSCI's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Redwood Scientific Technologies  (OTCPK:RSCI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Redwood Scientific Technologies Debt-to-Equity Related Terms

Redwood Scientific Technologies Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Redwood Scientific Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redwood Scientific Technologies Debt-to-Equity Chart

Redwood Scientific Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
N/A N/A 0.00 0.00

Redwood Scientific Technologies Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Debt-to-Equity N/A N/A 0.00 0.00

RSCI vs RAPH, FLGC, TXMD: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redwood Scientific Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redwood Scientific Technologies Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redwood Scientific Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Redwood Scientific Technologies's Debt-to-Equity falls into.


Redwood Scientific Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Redwood Scientific Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.195
=0.00

Redwood Scientific Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.195
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Redwood Scientific Technologies (RSCI) has a Debt-to-Equity of 0.00 as of Dec. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Redwood Scientific Technologies and its competitors.
Is Redwood Scientific Technologies' Debt-to-Equity too high?
Redwood Scientific Technologies' current Debt-to-Equity is 0.00.
How does Redwood Scientific Technologies' Debt-to-Equity compare to RAPH and FLGC?
Redwood Scientific Technologies' Debt-to-Equity of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Redwood Scientific Technologies and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redwood Scientific Technologies's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redwood Scientific Technologies stock overvalued right now?
Redwood Scientific Technologies (RSCI) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Redwood Scientific Technologies (RSCI), the current Debt-to-Equity is 0.00 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redwood Scientific Technologies Business Description

Address 418 Broadway, STE 4872, Albany, NY, USA, 12207
Redwood Scientific Technologies Inc is a pharmaceutical delivery company that develops, operates, and markets over-the-counter products in a sublingual oral thin film strip. RSCI has begun clinical trials on two new products to market for stopping the addiction to nicotine.